IPO Archives

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have read about AC Immune‘s ‘$700M IPO’ and thought, “gee, that can’t be right – that sum is roughly half of the total from all European companies […]

September 26, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 12 Sep 2016

CRISPR Therapeutics applies to go Public in another Massive IPO

The wait is over: CRISPR Therapeutics has turned up the heat on its rivals with an IPO filing of €80M, but this figure could be a lowball. Everyone saw it coming – the only question was, when would CRISPR Therapeutics file for an IPO? News arrived today that the company had finally applied to the US […]

September 12, 2016 - 3 minutesmins - By Evelyn Warner

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

europe biotech ey finance growth pharma industry 2016

News and Trends 12 Apr 2016

How was the Biotech Financial World in 2015? Unprecedented!

Biotech is still breaking funding records. A new report by EY provides an interesting analysis of how Biotech is doing, globally and in Europe. Although 2015 was the best for Biotech yet, but there is a slowdown coming – that’s the gist of EY’s recent report: ‘Beyond borders 2016: Biotech financing‘. This well-known auditing and […]

April 12, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 21 Mar 2016

This CEO was responsible for the Only German Biotech IPO in 2015…

Whilst at the Sachs conference last week, I had the chance to meet with Oliver Schacht, the CEO of Curetis. It’s the only German Biotech which went public last year and this was a good enough reason to have a chat (the company is also really interesting, obviously). Curetis is based in Stuttgart in the […]

March 21, 2016 - 1 minutemin - By Philip Hemme

News and Trends 26 Oct 2015

Financial Storm approaching? EU Biotechs start postponing their IPOs in London …

Biotech financing beats record over record since beginning of 2014. Financing has never been as high in Europe (though of course, we know this has always been the case for the US). Just look at Neil Woodford, famous british investor who raised €1.1Bn for its fund and injected it in many companies like Immuncore (2nd biggest VC round […]

October 26, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 6 Aug 2015

Here are 7 Biotech Stories you Must Read During the Holidays

The Holidays are a perfect time to enjoy the sun and relax peacefully on the beach but it’s also a great time to read inspiring stories about your favorite topic, Biotechs! For your delight, we bring you the most read biotech stories of this year. Discover or re-discover them and enjoy! January – The CRISPR’s Therapeutical revolution Six […]

August 6, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 29 Jul 2015

Erytech follows the path of DBV and Cellectis into the US stock exchange

Erytech Pharma, developer of an innovative ‘tumor starvation’ treatment, today announced that it plans to conduct a registered initial public offering in the United States and thus, plays in the major league with its French fellows DBV and Cellectis. It’s definitely the last trend in Biotech! European companies are queuing up to enter the US stock market. In […]

July 29, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

European Biotechs Outperform, Here is the Proof

We underwent great Biotech stories in 2014. However, was 2014 really a good year for the Biotech industry? EY released Beyond borders 2015, its 29th Biotechnology Industry Report. We summed up the most important details for you concerning the European Biotech sector. So, let’s go over a few statistics. First impression, the Biotech industry is definitely […]

July 20, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 22 Jun 2015

American Companies are Invading London’s Biotech Stock Market

[Update: On June 19, Puretech successfully raised $171M – approximately €150M – during its IPO, setting its market cap at €509M] Boston-based PureTech Health plans to raise €147M on the London stock market, following the path of Verseon, a San Diego-based bioinformatic company that raised €92M earlier this month. Is there a new American trend to earn cash in […]

June 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 11 Jun 2015

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pieris Pharmaceutical is planning to raise €31M in an surprisingly low US IPO. The company seeks to advance its early-stage pipeline with a special focus on its anemia treatment, Pieris’s most advanced candidate which recently completed the enrollment of its Phase I. Pieris’ pipeline might be premature, but it is ambitious. The company’s focus includes […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 May 2015

[UPDATE] Galapagos with €277.3M, made the Biggest European Biotech IPO ever on NASDAQ

[UPDATE 20/05/2015]: Galapagos announced the closing of its NASDAQ IPO, where the company raised a total of €277.3M. Galapagos has once again made the front page thanks to its unbeaten IPO. The company just raised €240M on Nasdaq, becoming the biggest European biotech IPO ever on the US stock market. The Belgium company just ranked […]

May 20, 2015 - 2 minutesmins - By Lourdes Riquelme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us